Trial Profile
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multi-Part, Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Aficamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions; First in man
- Sponsors Cytokinetics
- 28 Jan 2020 Status changed from active, no longer recruiting to completed.
- 11 Nov 2019 Planned number of patients changed from 108 to 120.
- 11 Nov 2019 Status changed from recruiting to active, no longer recruiting.